Shamburg News · 8-K filed Nov 12, 2026, 4:17 PM EST

ProMIS Neurosciences Reports Q3 2026 Results; Appoints Ivana Rubino Chief Commercial Officer

PMN · ProMIS Neurosciences Inc.

  • Earnings
  • Leadership change
  • Materiality: high

ProMIS Neurosciences Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $8.2 million, or $(0.89) per basic and diluted share, compared with a net loss of $11.6 million, or $(5.93) per share, a year earlier. Cash was $44.1 million as of September 30, 2026, which the Company expects to fund operations through 2027. The release also reaffirmed that unblinded 12-month topline data from the PRECISE-AD Phase 1b trial are expected in the first quarter of 2027 and disclosed the appointment of Ivana Rubino, Ph.D., as Chief Commercial Officer effective October 5, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-126260.

Written from the filing by Shamburg Markets. Figures are as reported by the company.